Resau JH - Search Results

1

Alteration of Met protooncogene product expression and prognosis in breast carcinomas.

Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF. Tsarfaty I, et al. Among authors: resau jh. Anal Quant Cytol Histol. 1999 Oct;21(5):397-408. Anal Quant Cytol Histol. 1999. PMID: 10560522

2

Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells.

Firon M, Shaharabany M, Altstock RT, Horev J, Abramovici A, Resau JH, Vande Woude GF, Tsarfaty I. Firon M, et al. Among authors: resau jh. Oncogene. 2000 May 11;19(20):2386-97. doi: 10.1038/sj.onc.1203557. Oncogene. 2000. PMID: 10828880

3

Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model.

Altstock RT, Stein GY, Resau JH, Tsarfaty I. Altstock RT, et al. Among authors: resau jh. Cytometry. 2000 Nov 1;41(3):155-65. Cytometry. 2000. PMID: 11042611

4

Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.

Stein GY, Yosef N, Reichman H, Horev J, Laser-Azogui A, Berens A, Resau J, Ruppin E, Sharan R, Tsarfaty I. Stein GY, et al. PLoS One. 2012;7(9):e45969. doi: 10.1371/journal.pone.0045969. Epub 2012 Sep 25. PLoS One. 2012. PMID: 23049908 Free PMC article.

5

Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker.

Golan M, Hizi A, Resau JH, Yaal-Hahoshen N, Reichman H, Keydar I, Tsarfaty I. Golan M, et al. Among authors: resau jh. Neoplasia. 2008 Jun;10(6):521-33. doi: 10.1593/neo.07986. Neoplasia. 2008. PMID: 18516289 Free PMC article.

6

Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells.

Ronen D, Altstock RT, Firon M, Mittelman L, Sobe T, Resau JH, Vande Woude GF, Tsarfaty I. Ronen D, et al. Among authors: resau jh. Cell Growth Differ. 1999 Feb;10(2):131-40. Cell Growth Differ. 1999. PMID: 10074906

7

The met proto-oncogene receptor and lumen formation.

Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. Tsarfaty I, et al. Among authors: resau jh. Science. 1992 Aug 28;257(5074):1258-61. doi: 10.1126/science.1387731. Science. 1992. PMID: 1387731

8

Grappling with metastatic risk: bringing molecular imaging of Met expression toward clinical use.

Hay R, Cao B, Tsarfaty I, Tsarfaty G, Resau J, Vande Woude G. Hay R, et al. J Cell Biochem Suppl. 2002;39:184-93. doi: 10.1002/jcb.10441. J Cell Biochem Suppl. 2002. PMID: 12552618 Review.

9

Met expression and sarcoma tumorigenicity.

Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Rong S, et al. Among authors: resau jh. Cancer Res. 1993 Nov 15;53(22):5355-60. Cancer Res. 1993. PMID: 7693339

10

In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I. Moshitch-Moshkovitz S, et al. Among authors: resau jh. Neoplasia. 2006 May;8(5):353-63. doi: 10.1593/neo.05634. Neoplasia. 2006. PMID: 16790084 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters